Kenneth S. Suslick

Professor Suslick received his B.S. from the California Institute of Technology in 1974, his Ph.D. from Stanford University in 1978, and came to the University of Illinois immediately thereafter. He has published more than 418 scientific papers, edited four books, and holds 56 patents and patent applications.

In addition to his academic research, Professor Suslick has had significant entrepreneurial experience. He was the lead consultant for Molecular Biosystems Inc. and part of the team that commercialized the first echo contrast agent for medical sonography, Albunex™, which became Optison™ by GE Healthcare. In addition, he was the founding consultant for VivoRx Pharmaceuticals and helped invent and commercialize Abraxane™, albumin microspheres with a paclitaxel core, which is the predominant current delivery system for taxol chemotherapy for breast cancer; VivoRx became Abraxis Bioscience, which was acquired by Celgene for $2.9 billion.   Most recently, Suslick invented, developed, and commercialized the "optoelectronic nose", a simple but highly effective technology for the identification and quantification of gas analytes. This has found important applications in the detection of toxic gases and explosives, the discrimination among complex odorants, and rapid diagnosis of disease based on their smell. He then co-founded ChemSensing, which began the commercialization of the Suslick group's optoelectronic nose technology and its successor, iSense Systems and Specific Diagnostics (both in Silicon Valley), for the biomedical applications of this unique sensor technology.